For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

In fact, more and more teens that meet certain weight and health criteria are going on GLP-1s after the FDA’s approval of ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Plus: Trump’s Republican party wins full Congress control; US producer prices rise stoking stubborn inflation fears; The ...

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication that the market for GLP-1 drugs could likely be a lot bigger. Based on data ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Allurion Third Quarter Earnings Call. All lines have been ...

"We look forward to releasing topline data results from our Phase 2 BMT-801 clinical study of our melanocortin-4 receptor ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...